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Introduction: In some community-based studies, lipoprotein-associated phospholipase A2 (Lp-PLA2) has been shown to
be independently predictive of future fatal and nonfatal cardiovascular disease (CVD) events. We tested the hypothesis
that Lp-PLA2 is independently predictive of mortality in high-risk patients from a vascular laboratory.
Methods: Between 1990 and 1994, patients seen in the previous 10 years for noninvasive lower extremity arterial testing
were invited to return for a vascular examination of the lower extremities. By medical record review, we identified 2265
eligible patients; of these, 508 returned for interviews, blood collection, and arterial examination and represent those who
had survived, could be located, and were willing to participate. The 508 subjects were followed up for an average of 6.7
years until the end of the study period on December 31, 2001. Vital status was ascertained by multiple searches of the
Social Security Death Index. The primary outcomes for this study were time to any, CVD, and coronary heart disease
(CHD) mortality.
Results: The mean age was 68.2 years, 88% were men, 87% were non-Hispanic white, 39.1% were diagnosed with
peripheral arterial disease only, 9.2% with other CVD only, and 28.5% with both peripheral arterial disease and other
CVD. During the entire follow-up period, 299 (59.7%) patients died, 167 from CVD, of which 88 deaths were due to
coronary heart disease. With adjustment for CVD risk factors and baseline peripheral arterial disease and other CVD, an
increment of one standard deviation in Lp-PLA2 activity was associated with a 40% higher risk for CHD mortality at 5
years of follow-up (P  .04). Additional adjustment for triglycerides, high-density lipoprotein, and low-density
lipoprotein cholesterol reduced this association to nonsignificance (hazard risk, 1.12).
Conclusion: In a vascular laboratory patient population, higher levels of LpPLA2 mass and activity were not significantly
associated with total, CVD, or CHD mortality at 5 years of follow-up and after adjustment for traditional CVD risk
factors and the presence of PAD and other CVD at baseline. An apparent elevated risk of CHD death associated with
elevated Lp-PLA2was largely explained by associated elevations in lipids and lipoproteins. ( J Vasc Surg 2007;46:500-6.)Lipoprotein-associated phospholipase A2 (Lp-PLA2),
also known as platelet-activating factor acetylhydrolase, is a
calcium-independent enzyme that cleaves oxidized and
polar phospholipids.1,2 In the circulation, Lp-PLA2 is
bound predominately to low-density lipoprotein choles-
terol (LDL-C) and has also been shown to have an affinity
for small, dense fractions of this class of cholesterol.3,4 In
the arterial wall, Lp-PLA2 is generated by monocytes,
macrophages, and T-lymphocytes and has been found in
intimal atherosclerotic plaques.5-7 More important, Lp-
PLA2 has been classified as a novel inflammatory marker
due to the production of oxidized free fatty acids and
lysophosphatidylcholines during oxidation of LDL-C.8
Because the rate of action of Lp-PLA2 on lipoproteins
depends on the activity and mass of this enzyme, both of
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500these measurements are required to understand its associa-
tion with morbidity and mortality.9 In previous community-
based studies, Lp-PLA2 activity and mass have been shown
to be independently predictive of future fatal and nonfatal
coronary heart disease events.10-15 To our knowledge,
however, no studies examining the potential association
between mortality and both Lp-PLA2 activity and mass
have been performed in a cohort of patients examined in a
vascular laboratory. Accordingly, we conducted a study to
compare the associations between both activity and mass of
Lp-PLA2 and both total and cardiovascular disease (CVD)
mortality in high-risk patients from a vascular laboratory.
METHODS
Subjects. Between 1990 and 1994, patients seen in
the previous 10 years for noninvasive lower extremity arte-
rial testing at the San Diego Veterans Administration Med-
ical Center (VAMC) or the University of California, San
Diego Medical Center (UCSDMC) vascular laboratories
were invited to return for a vascular examination of the
lower extremities using the same procedures as used previ-
ously. The invitations were derived from a listing of all
patients who had visited our vascular laboratories in the
previous 10 years, who had undergone a vascular examina-
tion, and who had provided permission to be contacted.
The order in which the participants were contacted was
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furthest in the past were contacted first. Enrollment was not
necessarily of consecutive patients.
The cohort consisted of individuals who were referred
by specialist or primary care physicians and included pa-
tients with and without CVD comorbidities. Baseline CVD
was defined as a history of myocardial infarction, stroke,
percutaneous transluminal angioplasty or stent, coronary
artery bypass graft, or carotid artery surgery. Baseline pe-
ripheral arterial disease (PAD) was defined as an ankle-
brachial index (ABI) of0.9 in either lower extremity or a
history of revascularization of the arteries in the lower
extremities. The visits between 1990 and 1994 are baseline
visits for these analyses.
Of 2265 patients with vascular laboratory visits in the
10-year time period before 1990 to 1994, 481 had died
before 1990 and another 1276 did not participate in the
follow-up visit. Thus, 508 patients returned for interviews
and represent those who had survived, could be located,
and were willing to participate. At the 1990 to 1994 visits,
fasting venous blood was collected and stored at –70°C.
Subjects who agreed to undergo repeat testing for PAD
signed a consent form approved by the University of Cali-
fornia San Diego Human Research Protection Program
and were interviewed in person using a structured ques-
tionnaire.
Vascular assessment. At the follow-up visit, a nonin-
vasive vascular examination including segmental blood
pressures and flow velocities was performed. Systolic blood
pressures were measured in both ankles and both arms by
sphygmomanometry and photoplethysmography. Photo-
plethysmographic assessment has been shown to give es-
sentially identical results toDoppler signal determination in
both the arms and legs.16 The ABI for both legs was
calculated using the arm with the higher systolic blood
pressure. The subjects were categorized as normal or with
PAD based on the ABI. PADwas defined as an ABI0.90,
the conventional cut-point in vascular laboratories. The
95% confidence interval (CI) of ABI reproducibility has
been reported to range from 0.10 to 0.15.17-19
Laboratory assessment. Blood samples collected at
the 1990 to 1994 visits were analyzed at that time for serum
lipids and lipoproteins at a standardized lipid analytical
laboratory using the Abbott VP Super System bichromatic
analyzer (Abbott Laboratories Abbott Park, Ill), which uses
direct enzymatic colorimetric assays. In 2006, Lp-PLA2
assays were conducted using plasma samples from fasting
venous blood obtained at the 1990 to 1994 and stored at
–70°C.
Lipoprotein-associated phospholipase A2 activity.
Lp-PLA2 activity (nmol/[min · mL]) was measured with
a colorimetric activity method (CAM); diaDexus Inc,
South San Francisco, Calif). Samples, standards, or controls
are added to wells of a nonbinding 96-well microplate,
followed by addition of CAM reaction buffer containing
substrate. In the presence of Lp-PLA2 enzyme, the sub-
strate is converted upon hydrolysis by the phospholipase
enzyme. The change in absorbance is immediately mea-sured at 405 nm over 60 to 180 seconds. The level of
Lp-PLA2 activity in nmol/(min · mL) is calculated from
the slope (OD405/min), based on a standard conversion
factor from a P-nitrophenol calibration curve. All samples
were measured in duplicate. The intra-assay coefficient of
variation (CV) was 4%. The inter-assay CV for six quality
controls across plates was between 4% and 6%.
Lipoprotein-associated phospholipase A2 mass.
Lp-PLA2 mass (ng/mL) was measured by the PLAC test, a
commercially available Lp-PLA2 enzyme-linked immuno-
absorbent assay kit (diaDexus Inc). The assay is a sandwich
enzyme immunoassay formulated with two specific mono-
clonal antibodies described by Caslake et al.20 The assay
system uses monoclonal anti-Lp-PLA2 antibody (2C10)
directed against Lp-PLA2 for solid phase immobilization
on microwell strips. After addition of assay buffer to the
antibody-coated microplate, samples, calibrators, or con-
trols are added to the wells and incubated for 2 hours. After
a washing step to remove any unbound antigen, a second
monoclonal anti-Lp-PLA2 antibody (4B4) labeled with the
enzyme horseradish peroxidase is used to detect the immo-
bilized antigen. The enzyme conjugate is incubated for 60
minutes, followed by another washing step.
Addition of the substrate, tetramethylbenzidine (TMB),
results in the development of a blue color which is stopped
appropriately with the addition of Stop Solution (1N
HCL), changing the color to yellow. The absorbance of the
enzymatic turnover of the substrate is determined spectro-
photometrically at 450 nm and is directly proportional to
the concentration of Lp-PLA2 present. A set of Lp-PLA2
calibrators is used to plot a standard curve of absorbance
versus Lp-PLA2 concentration from which the Lp-PLA2
concentration in the test sample can be determined. Dupli-
cate assays were performed for 26% of the samples; the
intra-assay coefficient of variation (CV) was 5%. The inter-
assay CV for quality controls was between 6% and 10%.
Outcomes ascertainment and classification. The
subjects were followed up for an average of 6.7 years until
the end of the study period on December 31, 2001. Be-
tween 1998 and 2001, the vital status of the 508 subjects
who participated in the follow-up visit was ascertained by
multiple searches of the Social Security Death Index, and
501 had adequate blood samples available for the pertinent
analysis. From this search, the place of death was recorded
and then used to request the pertinent death certificate.
Once received, the death certificate was reviewed and
coded by a certified nosologist using the International
Classification of Diseases, 9th edition (ICD-9). Mortality
from coronary heart disease was defined using the ICD-9
code range of 410 to 414, andmortality from any CVDwas
defined as ICD-9 code range of 410 to 414 or 420 to 438.
The coded underlying cause of death was used in these
analyses.
Statistical analysis. Continuous data are presented as
means standard deviations, and categoric data are shown
as frequencies with percents. All variables were examined
for normality. Those independent variables that deviated
from a Gaussian distribution were transformed to achieve
r necr
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ization were analyzed using nonparametric methods. Differ-
ences in age-adjusted and sex-adjusted mean values of the
independent variables by high vs low Lp-PLA2 status were
determined by analysis of covariance. Correlations were con-
ducted using the Spearman rank correlation method.
To determine the risk for incident mortality, separate
Cox proportional hazard models were constructed for Lp-
PLA2 activity and mass in a stepwise fashion. The first step
in each analysis consisted of adjustments for age and sex as
covariates of the Lp-PLA2 variable (ie, activity or mass).
The second step included the addition of traditional CVD
risk factors and baseline PADandotherCVD; in the third step
triglycerides were added; in the fourth step, high-density
lipoprotein cholesterol (HDL-C) was added; and finally, in
the fifth step LDL-C was added to the model. Hazard ratios
were determined for 5 years of follow-up. All analyses were
conducted using SAS 8.2 (SAS Institute, Cary, NC). A two-
tailed   0.05 was considered significant.
RESULTS
The age of the men (68.2 years) and women (68.1
years) in the study was not significantly different (P .93).
Sixty (12%) of the participants were women. A total of 196
subjects (39.1%) were diagnosed with PAD only, 46 (9.2%)
Table I. Age and sex adjusted cohort characteristics stratifi
mass above and below the mean
Risk factor
Lipoprot
Activity 146.3
(nmol/[min · mL])
A
(nm
BMI (kg/m2) 27.7
Waist circumference (cm) 99.7
Blood pressure
Systolic (mm Hg) 142.8
Diastolic (mm Hg) 78.3
Fasting plasma glucose (mg/dL) 132.4
Cholesterol
Total (mg/dL) 220.8
HDL (mg/dL) 43.3
LDL (mg/dL) 142.6
Triglycerides (mg/dL) 155.4
CRP (pg/mL) 0.52
Homocysteine (mol/L) 13.4
Lipoprotein (a) (pg/mL) 20.0
Serum amyloid A (pg/mL) 0.80
D-dimer (g/mL) 1.55
CD-40 ligand (pg/mL) 1314.3
NT-pro BNP (pg/mL) 559.2
PAI-1 (pg/mL) 20530.3
TNF- (pg/mL) 99.2
MCP-1 (pg/mL) 1530.4
Interleukin-6 (pg/mL) 32.1
Hypertension (%) 69.5
Diabetes (%) 27.1
Past or current smoker (%) 68.5
Pack-years 57.0
BMI, Body mass index; HDL, high-density lipoprotein; LDL, low-densi
natriuretic peptide; PAI-1, plasminogen activator inhibitor 1; TNF-, tumowere diagnosed with other CVD but not PAD, and 143(28.5%) were diagnosed with both PAD and other CVD.
Themean duration of follow-upwas 6.7 3.2 years. Of the
299 patients (59.7%) who died during the entire follow-up
period, 167 died of CVD, and 88 of these deaths were due
to coronary heart disease (CHD).
The mean Lp-PLA2 activity was 145.2  33.5 nmol/
([min · mL]), and the corresponding mean for Lp-PLA2
mass was 377.9  148.0 ng/mL. Those with an Lp-PLA2
activity level above the mean had significantly higher levels
of total and LDL-C as well as triglycerides, while also
having lower HDL-C (Table I). Notably, for the other
CVD risk factors or inflammatory markers studied, there
were no other significant differences between those with an
Lp-PLA2 activity above the mean compared with an Lp-
PLA2 activity below the mean.
For Lp-PLA2 mass, the associations were similar. Spe-
cifically, those above the mean for Lp-PLA2 mass had
significantly higher total and LDL-C levels and triglycer-
ides. Those above the mean did not have significantly
different HDL-C levels, but they did have significantly
higher levels of N-terminal pro-B-type natriuretic peptide
and monocyte chemotactic protein 1 levels. There were
also trends for higher C-reactive protein and plasminogen
activator inhibitor 1 (PAI-1), which were of borderline
y lipoprotein-associated phospholipase A2 activity and
ssociated phospholipase A2 (n  506)
P
y 146.3
in · mL]) P
Mass 367.7
(ng/mL)
Mass 367.7
(ng/mL)
26.8 .26 27.1 27.4 .67
98.2 .20 99.8 98.1 .14
43.4 .73 142.2 144.0 .33
78.3 .92 78.6 78.1 .57
30.1 .66 129.1 133.4 .42
97.6 .01 217.0 201.3 .01
48.8 .01 45.3 46.8 .20
19.6 .01 136.6 125.4 .01
23.5 .01 152.9 125.5 .01
0.58 .32 0.60 0.49 .08
14.5 .23 14.2 13.7 .57
19.7 .89 21.2 18.5 .23
1.13 .13 1.08 0.86 .32
1.29 .11 1.39 1.44 .79
97.3 .41 1503.9 1408.4 .78
56.1 .14 579.1 436.2 .04
12.9 .68 23268.5 16285.7 .06
93.5 .55 99.8 192.9 .55
34.5 .40 1810.9 1055.2 .01
16.4 .34 36.3 12.2 .14
64.9 .29 66.6 67.8 .79
33.6 .11 27.0 33.7 .11
71.1 .54 64.5 75.1 .01
58.4 .71 56.0 59.5 .38
protein; CRP, C-reactive protein; NT-pro BNP, N-terminal pro-B-type
osis factor-; MCP-1, monocyte chemotactic protein 1.ed b
ein-a
ctivit
ol/[m
1
1
1
1
1
15
4
190
1
13
ty liposignificance (P  .08, and P  .06 respectively).
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cantly different by sex and smoking status (Table II).
Compared with all other ethnic groups combined, non-
Hispanic whites had significantly higher Lp-PLA2 activity
(147.5 vs 130.0 nmol/[min · mL]). Levels of Lp-PLA2
mass were also higher in non-Hispanic whites, but these
differences did not reach significance. Conversely, those
with diabetes had significantly lower Lp-PLA2mass but not
activity levels. Of interest, those with a family history of
CHD or a personal history of CVD had significantly higher
Lp-PLA2 activity but not mass levels. Mean Lp-PLA2 ac-
tivity and mass levels were not significantly different by
PAD status.
After adjustment for age and sex, Lp-PLA2 activity and
mass were significantly correlated (r  0.55, P  .01).
Lp-PLA2 activity and mass were also significantly inversely
correlated with the ABI (r –0.12, P .01 and r –0.10,
P  .03; respectively). Table III shows the correlations
between Lp-PLA2 activity and mass with the CVD risk
factors and novel biomarkers. LDL-C had the strongest age
and sex-adjusted correlation with Lp-PLA2 activity (r 
0.45) followed by HDL-C (r  –0.24) and triglycerides
(r 0.19). The correlations between Lp-PLA2 activity and
waist circumference and body weight were modest and of
borderline significance. There were no significant associa-
tions between LP-PLA2 activity and fasting glucose and any
of the novel risk factors such as C-reactive protein, inter-
Table II. Mean lipoprotein-associated phospholipase A2
activity and mass levels for different cohort characteristics
Group N
Lipoprotein-associated phospholipase A2
Activity (nmol/
[min · mL]) P
Mass
(ng/mL) P
Sex
Male 441 147.9 Ref 387.3 Ref
Female 60 125.4 .01 308.9 .01
Ethnicity
NHW 436 147.5 Ref 381.1 Ref
Other 65 130 .01 356.6 .21
Smoking
Never 72 132.7 Ref 320.5 Ref
Quit 278 146 .01 368.7 .01
Current 151 149 .01 420.4 .01
Diabetes
No 348 146.4 Ref 389.2 Ref
Yes 153 142.4 .22 356.1 .02
FHx CHD
No 217 140.5 Ref 367.9 Ref
Yes 284 148.5 .01 384.4 .22
PAD
No 162 144.5 Ref 385.6 Ref
Yes 339 145.7 .72 377.7 .61
CVD
No 365 142.1 Ref 378.5 Ref
Yes 133 148.8 .02 380.9 .86
NHW, Non-Hispanic white; FHx, family history; CHD, coronary heart
disease; PAD, peripheral arterial disease; Ref, reference category; CVD,
cardiovascular disease.leukin 6, and D-dimer. With the same adjustment for ageand sex, Lp-PLA2 mass was significantly correlated with
LDL-C (r  0.18) and triglycerides (r  0.19), but not
HDL-C. Lp-PLA2 mass was also significantly correlated
with MCP-1 and PAI-1 (r  0.13 for both) but not with
any of the other novel biomarkers.
At 5 years of follow-up and in the Cox proportional
hazards models, there were no significant associations be-
tween Lp-PLA2mass or activity and total mortality or CVD
mortality. Similarly, no significant association was found
between Lp-PLA2 mass and CHD mortality. In a multiva-
riable Cox proportional hazard model adjusted for age and
sex, however, a one-standard-deviation increment of Lp-
PLA2 activity was significantly associated with a 40% (P 
.04) increased hazard for CHD mortality (Fig) that re-
mained essentially unchanged with additional adjustment
for smoking, hypertension, diabetes, family history of pre-
mature CHD, baseline PAD, and other CVD (hazard ratio
[HR], 1.37, 95% confidence interval [CI], 1.00 to 1.89).
Additional adjustment for triglycerides modestly attenu-
ated this association (HR, 1.34; 95% CI, 0.97 to 1.86).
WhenHDL-Cwas added to the model, however, there was
a substantial reduction in the hazard ratio to 1.25 (95% CI,
0.90 to 1.75), which was further reduced to 1.12 with
Table III. Age-adjusted and sex-adjusted correlations for
lipoprotein-associated phospholipase A2 mass and activity
Variable
Lipoprotein-associated
phospholipase A2
Activity Mass
Waist
circumference
0.09* 0.03
Body mass index 0.08 0.04
Body weight 0.08* 0.01
Waist-to-hip ratio 0.06 0.01
Fasting glucose 0.04 0.08
Blood pressure
Systolic 0.05 0.04
Diastolic 0.02 0.09*
HDL cholesterol 0.24† 0.02
LDL cholesterol 0.45† 0.18†
Triglycerides 0.19† 0.19†
Pack-years smoking 0.02 0.01
Interleukin-6 0.01 0.04
TNF- 0.04 0.08
MCP-1 0.03 0.13†
PAI-1 0.04 0.13†
NT-pro-BNP 0.01 0.08
CD-40 0.03 0.01
D-dimer 0.05 0.02
C-reactive protein 0.07 0.04
Serum amyloid A 0.06 0.04
Lipoprotein (a) 0.04 0.15
Homocysteine 0.01 0.03
HDL, High-density lipoprotein; LDL, low-density lipoprotein; TNF-,
Tumor necrosis factor-; MCP-1, monocyte chemotactic protein 1; PAI-1,
plasminogen activator inhibitor 1; NT-pro-BNP, N-terminal pro-B-type
natriuretic peptide.
*.05  P  .10.
†P  .05.additional adjustment for LDL-C (95% CI, 0.78 to 1.60).
w-den
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change the nature of these associations.
To determine if the mortality risks differed by baseline
comorbidity status, we stratified the cohort into the follow-
ing groups: (1) other CVD only, (2) PAD only, (3) CVD
and PAD, and (4) no CVD or PAD. We then conducted
the same Cox regression analyses as described for the entire
cohort. These exploratory analyses uncovered significant
associations with Lp-PLA2 mass and both CVD and CHD
mortality in the other CVD only group that was not further
attenuated by adjustment for HDL-C and LDL-C. For the
PAD-only and CVD-plus-PAD groups, no significant asso-
ciations were found with Lp-PLA2 mass and activity with
mortality. Because the sample size for these subsets was
relatively small, these results should be interpreted with
caution.
DISCUSSION
In this cohort study of patients from a vascular labora-
tory and after adjustment for multiple CVD risk factors and
baseline PAD and other CVD, higher levels of Lp-PLA2
activity were associated with significantly higher risks for
CHD mortality. However, additional adjustment for
HDL-C and LDL-C significantly attenuated this associa-
tion so that it was no longer statistically significant. We also
note that among those with other CVD at baseline and
after adjustment for the CVD risk factors, Lp-PLA2 mass
was significantly associated with an increased hazard for
CVD and CHD mortality. These associations were not
0.00
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0.40
0.60
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2.00
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CVD RFs + baseline CVD & PAD
CVD RFs + baseline CVD & PAD + trigl
CVD RFs + baseline CVD & PAD + trigl
CVD RFs + baseline CVD & PAD + trigl
Fig. Risks at 5 years, presented with 95% confidence in
heart disease (CHD) mortality associated with standard
activity. CVD risk factors: age, sex, smoking, diabetes,
arterial disease; HDL, high-density lipoprotein; LDL, loattenuated with additional adjustment for HDL-C andLDL-C. These results suggest a complex relationship be-
tween both Lp-PLA2 mass and activity and CVD events.
The lack of statistical significance between Lp-PLA2
activity and CHD mortality after adjustment for HDL-C
and LDL-C in our study may be due to our relatively small
cohort. The rationale for this assertion is that several other
studies have found statistically significant associations be-
tween incident CVD events and Lp-PLA2 activity at 7 years
of follow-up that were of similar magnitude to ours. Spe-
cifically, after adjustment for traditional CVD risk factors, a
one-standard-deviation increment in Lp-PLA2 was associ-
ated with hazard ratios of 1.30, 1.23, and 1.18 in the
Mayo,14 Monitoring of Trends and Determinants in Car-
diovascular Diseases (MONICA),20 and West of Scotland
Coronary Prevention Study (WOSCOPS)9 studies, respec-
tively. Combined with our findings, these results demon-
strate a relatively consistent magnitude of association be-
tween higher levels of Lp-PLA2 and CVD risk across
different study populations that is independent of multiple
risk factors.
Atherosclerosis is a chronic reparative inflammatory
process21 and the underlying mechanism for the develop-
ment the majority of CVD events. The immune/inflamma-
tory pathway of this process is multifaceted and complex.22
A key step is the oxidation of lipoproteins in the intima of
the arterial wall leading to an expansion of the inflamma-
tion by the recruitment of cells that elaborate vasoactive
cytokines.23,24 Lp-PLA2 has been proposed as an inflam-
matory marker involved in the atherosclerotic process.2
CVD CHD
ortality
es
es + HDL cholesterol
es + HDL cholesterol + LDL cholesterol
l, for total, cardiovascular disease (CVD), and coronary
increments of lipoprotein-associated phospholipase A2
rtension, and family history of CHD. PAD, peripheral
sity lipoprotein.M
ycerid
ycerid
ycerid
terva
ized
hypeSpecifically, Lp-PLA2 participates in the oxidative modifi-
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and generating lysophosphatidylcholine and oxidized free
fatty acids. These free fatty acids promote inflammatory
processes present at every stage of atherogenesis25 and
result in diverse inflammatory effects on various cell
types.26 These properties suggest that Lp-PLA2 would be a
risk factor for the development and progression of athero-
sclerotic CVD.
From this context, some previous community-based
studies have demonstrated Lp-PLA2 to be a significant risk
marker for CVD events. For example, Oei et al14 reported
nearly twofold higher relative risks for either incident CHD
or stroke that were independent of CVD risk factors and
HDL-C levels, whereas other studies have demonstrated
the risk associated with higher levels of Lp-PLA2 to be
independent of both CVD risk factors and other inflamma-
tory markers such as C-reactive protein.13 In the Athero-
sclerosis Risk in Communities (ARIC) study, however,
Lp-PLA2 was significantly associated with CHD events
during 6 years only in those with an LDL-C level of 130
mg/dL,12 and we did not observe an interaction between
LDL-C and Lp-PLA2 for incident CHD (data not shown).
Finally, the Women’s Health Study (WHS) found no sig-
nificant association between Lp-PLA2 and CVD events
after adjustment for CVD risk factors.11
A significant association with CVD events has been
demonstrated in clinical populations.15 In the Pravastatin
or Atorvastatin Evaluation and Infection Therapy –
Thrombolysis in Myocardial Infarction 22 (PROVE IT-
TIMI 22) trial, those in the highest quintile of Lp-PLA2
activity (but not mass) had a 33% higher risk for recurrent
CVD events.27 Similarly, Brilakis et al15 reported a 28%
higher risk for major incident events during 4 years of
follow-up in those undergoing clinically indicated angiog-
raphy. The Thrombogenic Factors and Recurrent Coro-
nary Events (THROMBO) postinfarction study reported
significant associations between Lp-PLA2 activity and re-
current coronary events at a magnitude similar to our
findings.28
Other studies have investigated the potential associa-
tion between Lp-PLA2 and surrogate markers of CVD.
Patients with endothelial dysfunction in the coronary arter-
ies have been shown to have significantly higher levels of
Lp-PLA2, whereas those with Lp-PLA2 in the highest
tertile have more than three times higher odds for having
coronary artery endothelial dysfunction.29 Similarly, after
adjustment for age, a one-standard-deviation increment of
both Lp-PLA2 mass and activity has been associated with
40% higher odds for the presence of coronary artery cal-
cium. With adjustment for covariates, including LDL-C,
HDL-C, triglycerides, and C-reactive protein, a statistically
significant association remained for Lp-PLA2 mass (odds
ratio [OR], 1.28; 95% CI, 1.03 to 1.60) but not for activity
(OR, 1.09; 95% CI, 0.84 to 1.42).30 Finally, investigators
from the Rotterdam study assessed the association between
Lp-PLA2 and carotid intimal medial thickness, carotid
plaques, calcified atherosclerosis of the abdominal aorta,
and the ABI. The age-adjusted OR of having atherosclero-sis at any site for the highest versus the lowest tertile of
Lp-PLA2 activity was 1.86 (95% CI, 1.01 to 3.43) in men
and 1.60 (95% CI, 1.08 to 2.37) in women. Notably, after
additional adjustment for cholesterol, these associations
attenuated to nonsignificance. The ORs of having athero-
sclerosis at specific sites followed a similar pattern.31
The participants in our study were a relatively small
proportion of the cohort of individuals seen in the previous
10 years; therefore, the results of this study may be influ-
enced by selection and survival biases. Men comprised 92%
of subjects who did not participate in the study (nonpartic-
ipants) versus 87% of study subjects. The mean age of the
nonparticipants at the midpoint of the study was 70 years,
which was similar to the study subjects’ 68 years. In the
nonparticipants group, the mean baseline ABI was 0.85
compared with 0.90 in the study subjects. These results
suggest that the participants were modestly younger and
had slightly less advanced disease than the nonparticipants
but were otherwise comparable.
CONCLUSION
Our study in a vascular laboratory cohort concurs with
most earlier studies suggesting that Lp-PLA2 is a biomarker
for and possibly plays a role in CVD events as well as
subclinical CVD. Similarly, our data suggest that some, but
likely not all, of this risk can be attributed to correlations
with lipoprotein cholesterol fractions. Finally, differences
exist for the associations by Lp-PLA2 mass and activity,
which at this time do not appear to follow a consistent
pattern. Given the complexity of the findings to date,
further studies are recommended to elucidate the relation-
ship between this novel inflammatory marker and risk for
future CVD morbidity and mortality.
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